1951.HK
Jinxin Fertility Group Limited [1951.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1951.HK Stock Summary
Top 10 Correlated ETFs
1951.HK
Top 10 Correlated Stocks
1951.HK
In the News
1951.HK Financial details
Company Rating
Strong Buy
Market Cap
6.66B
Income
528.94M
Revenue
4.68B
Book val./share
3.53
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
3.23K
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
52.69
Forward P/E
-
PEG
14.05
P/S
2.93
P/B
0.74
P/C
8.07
P/FCF
-16.61
Quick Ratio
0.51
Current Ratio
0.69
Debt / Equity
0.25
LT Debt / Equity
0.18
-
-
EPS (TTM)
0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-65.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.18%
Revenue last 5Y
20.73%
Revenue Q/Q
8.78%
EPS Q/Q
-383.7%
-
-
-
-
SMA20
-6.64%
SMA50
5.29%
SMA100
-39.8%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
1%
ROC
0.02%
Gross Margin
37%
Oper. Margin
13%
Profit Margin
5%
Payout
131%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.05-5.8
52W High
-54.8%
52W Low
+13%
RSI
40.01
Rel Volume
0.3
Avg Volume
15.78M
Volume
4.66M
Perf Week
-12.06%
Perf Month
-3.83%
Perf Quarter
-37.57%
Perf Half Y
-41.3%
-
-
-
-
Beta
1.438
-
-
Volatility
0.09%, 0.11%
Prev Close
-2.16%
Price
2.26
Change
-2.59%
1951.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.39 | 0.75 | 0.59 | 0.74 | 0.95 | |
| Net income per share | 0.07 | 0.19 | 0.1 | 0.14 | 0.05 | |
| Operating cash flow per share | 0.15 | 0.21 | 0.13 | 0.14 | 0.22 | |
| Free cash flow per share | 0.14 | 0.08 | 0.02 | 0.11 | -0.17 | |
| Cash per share | 0.54 | 1.48 | 1 | 0.69 | 0.56 | |
| Book value per share | 1.84 | 3.42 | 3.03 | 3.45 | 3.46 | |
| Tangible book value per share | 0.03 | 1.44 | 1.12 | 0.33 | -0.38 | |
| Share holders equity per share | 1.84 | 3.42 | 3.03 | 3.45 | 3.46 | |
| Interest debt per share | 0.02 | 0.09 | 0.09 | 0.7 | 1.59 | |
| Market cap | 18.15B | 20.46B | 31.75B | 17.62B | 15.89B | |
| Enterprise value | 16.97B | 20.06B | 31.48B | 18.84B | 18.73B | |
| P/E ratio | 108.97 | 49.95 | 126.19 | 51.83 | 131.22 | |
| Price to sales ratio | 19.69 | 12.41 | 22.27 | 9.58 | 6.72 | |
| POCF ratio | 50.93 | 45.21 | 103.08 | 51.29 | 29.34 | |
| PFCF ratio | 54.12 | 116.72 | 758.01 | 66.83 | -38.06 | |
| P/B Ratio | 4.16 | 2.72 | 4.36 | 2.06 | 1.84 | |
| PTB ratio | 4.16 | 2.72 | 4.36 | 2.06 | 1.84 | |
| EV to sales | 18.41 | 12.17 | 22.07 | 10.25 | 7.92 | |
| Enterprise value over EBITDA | 53.18 | 32.93 | 94.84 | 38.14 | 39.33 | |
| EV to operating cash flow | 47.61 | 44.33 | 102.19 | 54.87 | 34.57 | |
| EV to free cash flow | 50.59 | 114.46 | 751.46 | 71.48 | -44.84 | |
| Earnings yield | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | |
| Free cash flow yield | 0.02 | 0.01 | 0 | 0.01 | -0.03 | |
| Debt to equity | 0 | 0.02 | 0.03 | 0.2 | 0.45 | |
| Debt to assets | 0 | 0.02 | 0.02 | 0.13 | 0.26 | |
| Net debt to EBITDA | -3.71 | -0.65 | -0.83 | 2.48 | 5.95 | |
| Current ratio | 1.04 | 7.85 | 4.78 | 2.37 | 0.69 | |
| Interest coverage | 6.05 | 56.85 | 17.75 | 17.56 | 3.97 | |
| Income quality | 1.29 | 1.1 | 1.22 | 1.01 | 4.47 | |
| Dividend Yield | 0.01 | 0.02 | 0 | 0.05 | 0.01 | |
| Payout ratio | 0.74 | 0.8 | 0.59 | 2.84 | 1.31 | |
| Sales general and administrative to revenue | 0.07 | 0.13 | 0.19 | 0.18 | 0.19 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.68 | 0.5 | 0.52 | 0.62 | 0.64 | |
| Capex to operating cash flow | -0.06 | -0.61 | -0.86 | -0.23 | -1.77 | |
| Capex to revenue | -0.02 | -0.17 | -0.19 | -0.04 | -0.41 | |
| Capex to depreciation | -0.5 | -2.46 | -2.04 | -0.47 | -3.67 | |
| Stock based compensation to revenue | 0 | 0.02 | 0.06 | 0.04 | 0.01 | |
| Graham number | 1.71 | 3.79 | 2.68 | 3.26 | 1.94 | |
| ROIC | 0.05 | 0.05 | 0.02 | 0.03 | 0.02 | |
| Return on tangible assets | 0.08 | 0.09 | 0.06 | 0.07 | 0.02 | |
| Graham Net | -0.3 | 0.91 | 0.33 | -0.85 | -1.95 | |
| Working capital | 58.72M | 2.99B | 2.1B | 1.47B | -860.1M | |
| Tangible asset value | 64.98M | 3.18B | 2.69B | 826.15M | -954.27M | |
| Net current asset value | -622.99M | 2.13B | 951.23M | -1.53B | -4.59B | |
| Invested capital | 0 | 0.02 | 0.03 | 0.2 | 0.45 | |
| Average receivables | 42.43M | 62.09M | 68.14M | 204.55M | 290.95M | |
| Average payables | 98.63M | 141.95M | 136.74M | 144.58M | 196.71M | |
| Average inventory | 17.62M | 21.32M | 25.78M | 36.14M | 54.68M | |
| Days sales outstanding | 31.78 | 9.72 | 23.64 | 62.87 | 40.93 | |
| Days payables outstanding | 102.58 | 61.83 | 56.25 | 53.55 | 59.56 | |
| Days of inventory on hand | 11.87 | 11.45 | 10.81 | 16.01 | 15.73 | |
| Receivables turnover | 11.48 | 37.55 | 15.44 | 5.81 | 8.92 | |
| Payables turnover | 3.56 | 5.9 | 6.49 | 6.82 | 6.13 | |
| Inventory turnover | 30.75 | 31.89 | 33.77 | 22.8 | 23.2 | |
| ROE | 0.04 | 0.05 | 0.03 | 0.04 | 0.01 | |
| Capex per share | -0.01 | -0.13 | -0.11 | -0.03 | -0.38 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.35 | 0.39 | 0.41 | 0.49 | 0.47 | |
| Net income per share | 0.06 | 0.07 | 0.07 | -0.03 | 0.08 | |
| Operating cash flow per share | 0.07 | 0.07 | 0.1 | 0.11 | 0.12 | |
| Free cash flow per share | 0.06 | 0.05 | -0.24 | 0.1 | 0.08 | |
| Cash per share | 1.27 | 0.69 | 0.43 | 0.56 | 0.28 | |
| Book value per share | 3.43 | 3.43 | 3.12 | 3.45 | 3.53 | |
| Tangible book value per share | 1.58 | 0.33 | 0.16 | -0.38 | 0.09 | |
| Share holders equity per share | 3.43 | 3.43 | 3.12 | 3.45 | 3.53 | |
| Interest debt per share | 0.08 | 0.69 | 1.4 | 1.55 | 0.88 | |
| Market cap | 40.26B | 17.73B | 17.02B | 15.95B | 10.92B | |
| Enterprise value | 38.6B | 18.96B | 20.05B | 18.78B | 12.95B | |
| P/E ratio | 64.67 | 24.06 | 22.38 | -57.76 | 12.22 | |
| Price to sales ratio | 46.86 | 18.1 | 14.96 | 13 | 8.19 | |
| POCF ratio | 230.82 | 104.91 | 62.35 | 59.35 | 32.43 | |
| PFCF ratio | 271.56 | 153.72 | -25.93 | 66.76 | 45.34 | |
| P/B Ratio | 4.76 | 2.08 | 1.98 | 1.85 | 1.08 | |
| PTB ratio | 4.76 | 2.08 | 1.98 | 1.85 | 1.08 | |
| EV to sales | 44.92 | 19.36 | 17.62 | 15.32 | 9.71 | |
| Enterprise value over EBITDA | 164.82 | 72.95 | 66.89 | 106.46 | 35 | |
| EV to operating cash flow | 221.27 | 112.17 | 73.45 | 69.9 | 38.46 | |
| EV to free cash flow | 260.31 | 164.36 | -30.55 | 78.63 | 53.76 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0 | 0.02 | |
| Free cash flow yield | 0 | 0.01 | -0.04 | 0.01 | 0.02 | |
| Debt to equity | 0.02 | 0.2 | 0.45 | 0.45 | 0.25 | |
| Debt to assets | 0.02 | 0.13 | 0.26 | 0.26 | 0.17 | |
| Net debt to EBITDA | -7.12 | 4.72 | 10.11 | 16.07 | 5.48 | |
| Current ratio | 6.56 | 2.37 | 0.77 | 0.69 | 0.95 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.12 | 0.92 | 1.44 | -3.89 | 1.51 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0 | 0 | 0 | -2.3 | 0.05 | |
| Sales general and administrative to revenue | 0.17 | 0.19 | 0.16 | 0.22 | 0.14 | |
| Research and developement to revenue | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.46 | 0.62 | 0.55 | 0.64 | 0.65 | |
| Capex to operating cash flow | -0.15 | -0.32 | -3.4 | -0.11 | -0.28 | |
| Capex to revenue | -0.03 | -0.05 | -0.82 | -0.02 | -0.07 | |
| Capex to depreciation | -0.39 | -0.52 | -7.85 | -0.21 | -0.77 | |
| Stock based compensation to revenue | 0.06 | 0.02 | 0.02 | 0.01 | 0 | |
| Graham number | 2.21 | 2.39 | 2.2 | 1.46 | 2.5 | |
| ROIC | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Return on tangible assets | 0.03 | 0.04 | 0.03 | -0.01 | 0.04 | |
| Graham Net | 0.6 | -0.84 | -1.79 | -1.94 | -1.42 | |
| Working capital | 3.09B | 1.47B | -620.69M | -860.1M | -83.32M | |
| Tangible asset value | 3.9B | 826.15M | 443.2M | -954.27M | 250.79M | |
| Net current asset value | 1.89B | -1.53B | -4.24B | -4.59B | -3.5B | |
| Invested capital | 0.02 | 0.2 | 0.45 | 0.45 | 0.25 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 14.09 | 29.1 | 24.22 | 19.46 | 17.02 | |
| Days payables outstanding | 25.58 | 24.67 | 28.03 | 27.42 | 28.15 | |
| Days of inventory on hand | 3.78 | 7.37 | 4.83 | 7.24 | 5.47 | |
| Receivables turnover | 6.39 | 3.09 | 3.72 | 4.62 | 5.29 | |
| Payables turnover | 3.52 | 3.65 | 3.21 | 3.28 | 3.2 | |
| Inventory turnover | 23.78 | 12.21 | 18.65 | 12.43 | 16.46 | |
| ROE | 0.02 | 0.02 | 0.02 | -0.01 | 0.02 | |
| Capex per share | -0.01 | -0.02 | -0.34 | -0.01 | -0.03 |
1951.HK Frequently Asked Questions
What is Jinxin Fertility Group Limited stock symbol ?
Jinxin Fertility Group Limited is a CN stock and trading under the symbol 1951.HK
What is Jinxin Fertility Group Limited stock quote today ?
Jinxin Fertility Group Limited stock price is $2.26 today.
Is Jinxin Fertility Group Limited stock public?
Yes, Jinxin Fertility Group Limited is a publicly traded company.
Company Profile
- Volume Average 15.78M
- Market Capitalization 6.66B
- Employee 3.23K
- CEO Mr. Yang Dong
- Headquarters Chengdu,CN
- IPO Date 2019-06-25
-
Website
https://www.jxr-fertility.com 
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.
